| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sanguinarine (SANG) — a benzophenanthridine alkaloid isolated primarily from Sanguinaria canadensis (bloodroot) and other Papaveraceae species. Potent redox-active, DNA-intercalating phytochemical studied extensively in preclinical oncology. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Limited human PK data; rapid reactivity and protein binding likely restrict systemic exposure. Toxicity (oral mucosal injury, cytotoxicity) limits therapeutic window. In-vitro vs oral exposure: Many anti-cancer effects occur at micromolar concentrations unlikely achievable systemically via safe oral dosing (qualifier: high concentration only for direct cytotoxicity). Clinical evidence status: Preclinical oncology only; no validated RCT cancer indication. Safety concerns limit development. Extracted from bloodroot plant from whose scientific name, Sanguinaria canadensis, its name is derived; the Mexican prickly poppy; Chelidonium majus; and Macleaya cordata.Sanguinarine — Cancer vs Normal Cell Pathway Map
TSF legend: |
| Source: HalifaxProj(inhibit) |
| Type: |
| Transcription factor that regulates gene expression in response to a variety of stimuli. Activator protein-1 (AP-1) is a transcription factor that consists of a diverse group of members including Jun, Fos, Maf, and ATF. AP-1 involves a number of processes such as proliferation, migration, and invasion in cells. Dysfunctional AP-1 activity is associated with cancer initiation, development, invasion, migration and drug resistance. , some small molecule inhibitors targeting AP-1 have been developed and tested, showing some anticancer effects.AP-1 has been described be overexpressed in many tumors, including triple-negative breast cancer (TNBC), colon cancer, classical Hodgkin’s disease, and anaplastic large cell lymphoma (ALCL). |
| 1090- | SANG, | Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. |
| - | in-vitro, | BC, | MCF-7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:147 Target#:11 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid